Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARCIK-CD19 in Relapsed/Refractory B-cell ALL Post-HSCT
NCT03389035Phase 2Completed
- Sponsor
- Fondazione Matilde Tettamanti
- Start
- Dec 2017
- Primary completion
- Mar 2021
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of CARCIK-CD19 in acute lymphoblastic leukemia (ALL), sponsored by Fondazione Matilde Tettamanti. Started Dec 2017; status: completed.
02
Drugs
CARCIK-CD19
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT03389035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03389035.